About

Bigfoot Biomedical provides solutions for individuals with Type 1 and Type 2 diabetes who need insulin therapy through a digital drug delivery platform. This platform simplifies insulin management and offers ongoing support, allowing healthcare providers to monitor patients remotely. The company operates on a subscription-based model, ensuring continuous access to its services for both healthcare providers and patients. Bigfoot Biomedical's goal is to make diabetes care simpler and more accessible, ultimately improving health equity and reducing the burden of diabetes.

Simplify's Take

What believers are saying

• Abbott's acquisition provides Bigfoot with increased resources and distribution channels.
• Recognition as an innovative company enhances Bigfoot's brand reputation and attracts partners.
• Partnerships for remote monitoring position Bigfoot to capitalize on telehealth growth.

What critics are saying

• Increased competition from Surf Bio's drug stabilization platform in low-income countries.
• Abbott's acquisition may disrupt Bigfoot's current business model and focus.
• Insulet's acquisition limits Bigfoot's ability to compete in the pump market.

What makes Bigfoot Biomedical unique

• Bigfoot Biomedical offers a comprehensive digital drug delivery platform for insulin management.
• The company integrates with Abbott's FreeStyle Libre CGM for real-time glycemic alerts.
• Bigfoot Biomedical uses a subscription model for continuous care and monitoring.

Help us improve and share your feedback! Did you find this helpful?

YesNo